Meeting
2024 ASCO Annual Meeting
Post-progression survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received darolutamide or placebo: Post hoc analysis of ARASENS.
Authors
Marc-Oliver Grimm
Jena University Hospital, Jena, Germany
Marc-Oliver Grimm , Matthew Raymond Smith , Maha H. A. Hussain , Fred Saad , Karim Fizazi , Natasha Littleton , Noman Paracha , Shankar Srinivasan , Frank Verholen , Bertrand F. Tombal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT02799602
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 5083)
DOI
10.1200/JCO.2024.42.16_suppl.5083
Abstract #
5083
Poster Bd #
489
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease.
First Author: Martin W. Schoen
Poster
2018 Genitourinary Cancers Symposium
ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Matthew Raymond Smith
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival outcomes in metastatic castration-resistant prostate cancer in the up-front treatment era.
First Author: Shunsuke Kamijo
Poster
2023 ASCO Genitourinary Cancers Symposium
Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.
First Author: Patrick Heckman